Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04401410 · ClinicalTrials.gov registry record · Phase 1
Anti-SARS Cov-2 T Cell Infusions for COVID 19
A Phase 1 study, sponsored by Baylor College of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04401410 is a Phase 1 study that was terminated before completion, run by Baylor College of Medicine. The registered enrollment target is 4 participants.
The verdict
NCT04401410, a Phase 1 study, was terminated before completion, sponsored by Baylor College of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a dose-finding safety trial followed by a randomized pilot trial comparing administration of SARS-CoV2-specific T cells (SARS-CoVSTs) to standard of care treatment in hospitalized patients with COVID19 who are at high risk of requiring mechanical ventilation. The SARS-CoVSTs lines have been made at Baylor College of Medicine from healthy donors who have made a full recovery from COVID19. These cell lines were frozen for later use and will be thawed and used to treat patients who meet the eligibility criteria.
Interventions
- BIOLOGICAL Dose Finding Phase (MTD)
- BIOLOGICAL Partially HLA-matched SARS-CoVSTs
- OTHER Routine care (no SARS-CoVSTs)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-11-04 |
| Est. Completion | 2021-10-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04401410
The ClinicalTrials.gov registry entry for NCT04401410 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dose Finding Phase (MTD) is the first listed.
NCT04401410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04401410 about?
NCT04401410 is a clinical study titled "Anti-SARS Cov-2 T Cell Infusions for COVID 19". This is a dose-finding safety trial followed by a randomized pilot trial comparing administration of SARS-CoV2-specific T cells (SARS-CoVSTs) to standard of care treatment in hospitalized patients with COVID19 who are at high risk of requiring mechanical ventilation. The SARS-CoVSTs lines have been...
What is the current status of trial NCT04401410?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2020-11-04. Estimated completion is 2021-10-12.
What interventions are being tested in trial NCT04401410?
The interventions under investigation include: Dose Finding Phase (MTD) (BIOLOGICAL), Partially HLA-matched SARS-CoVSTs (BIOLOGICAL), Routine care (no SARS-CoVSTs) (OTHER).
Who is sponsoring clinical trial NCT04401410?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.